Literature DB >> 27267713

Angiotensin Type-2 Receptors Influence the Activity of Vasopressin Neurons in the Paraventricular Nucleus of the Hypothalamus in Male Mice.

Annette D de Kloet1, Soledad Pitra1, Lei Wang1, Helmut Hiller1, David J Pioquinto1, Justin A Smith1, Colin Sumners1, Javier E Stern1, Eric G Krause1.   

Abstract

It is known that angiotensin-II acts at its type-1 receptor to stimulate vasopressin (AVP) secretion, which may contribute to angiotensin-II-induced hypertension. Less well known is the impact of angiotensin type-2 receptor (AT2R) activation on these processes. Studies conducted in a transgenic AT2R enhanced green fluorescent protein reporter mouse revealed that although AT2R are not themselves localized to AVP neurons within the paraventricular nucleus of the hypothalamus (PVN), they are localized to neurons that extend processes into the PVN. In the present set of studies, we set out to characterize the origin, phenotype, and function of nerve terminals within the PVN that arise from AT2R-enhanced green fluorescent protein-positive neurons and synapse onto AVP neurons. Initial experiments combined genetic and neuroanatomical techniques to determine that γ-aminobutyric acid (GABA)ergic neurons derived from the peri-PVN area containing AT2R make appositions onto AVP neurons within the PVN, thereby positioning AT2R to negatively regulate neuroendocrine secretion. Subsequent patch-clamp electrophysiological experiments revealed that selective activation of AT2R in the peri-PVN area using compound 21 facilitates inhibitory (ie, GABAergic) neurotransmission and leads to reduced activity of AVP neurons within the PVN. Final experiments determined the functional impact of AT2R activation by testing the effects of compound 21 on plasma AVP levels. Collectively, these experiments revealed that AT2R expressing neurons make GABAergic synapses onto AVP neurons that inhibit AVP neuronal activity and suppress baseline systemic AVP levels. These findings have direct implications in the targeting of AT2R for disorders of AVP secretion and also for the alleviation of high blood pressure.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27267713      PMCID: PMC4967126          DOI: 10.1210/en.2016-1131

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  60 in total

1.  Characterization of a novel tonic gamma-aminobutyric acidA receptor-mediated inhibition in magnocellular neurosecretory neurons and its modulation by glia.

Authors:  Jin Bong Park; Silvia Skalska; Javier E Stern
Journal:  Endocrinology       Date:  2006-05-04       Impact factor: 4.736

2.  Blood-borne angiotensin II acts in the brain to influence behavioral and endocrine responses to psychogenic stress.

Authors:  Eric G Krause; Annette D de Kloet; Karen A Scott; Jonathan N Flak; Kenneth Jones; Michael D Smeltzer; Yvonne M Ulrich-Lai; Stephen C Woods; Steven P Wilson; Lawrence P Reagan; James P Herman; Randall R Sakai
Journal:  J Neurosci       Date:  2011-10-19       Impact factor: 6.167

3.  Brain microglial cytokines in neurogenic hypertension.

Authors:  Peng Shi; Carlos Diez-Freire; Joo Yun Jun; Yanfei Qi; Michael J Katovich; Qiuhong Li; Srinivas Sriramula; Joseph Francis; Colin Sumners; Mohan K Raizada
Journal:  Hypertension       Date:  2010-06-14       Impact factor: 10.190

4.  Forebrain GABAergic projections to locus coeruleus in mouse.

Authors:  Eugene L Dimitrov; Yuchio Yanagawa; Ted B Usdin
Journal:  J Comp Neurol       Date:  2013-07-01       Impact factor: 3.215

5.  Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats.

Authors:  S Bosnyak; I K Welungoda; A Hallberg; M Alterman; R E Widdop; E S Jones
Journal:  Br J Pharmacol       Date:  2010-01-28       Impact factor: 8.739

6.  Arginine vasopressin and oxytocin responses to angiotensin II are mediated by AT1 receptor subtype in normal men.

Authors:  P Chiodera; R Volpi; A Caiazza; N Giuliani; M G Magotti; V Coiro
Journal:  Metabolism       Date:  1998-08       Impact factor: 8.694

7.  Angiotensin AT1 receptor-mediated vasopressin release and drinking are potentiated by an AT2 receptor antagonist.

Authors:  S Höhle; H Spitznagel; W Rascher; J Culman; T Unger
Journal:  Eur J Pharmacol       Date:  1995-03-14       Impact factor: 4.432

8.  A peripherally administered, centrally acting angiotensin II AT2 antagonist selectively increases brain AT1 receptors and decreases brain tyrosine hydroxylase transcription, pituitary vasopressin and ACTH.

Authors:  Miroslava Macova; Jaroslav Pavel; Juan M Saavedra
Journal:  Brain Res       Date:  2008-11-12       Impact factor: 3.252

9.  The effect of central injection of angiotensin-converting enzyme inhibitor and the angiotensin type 1 receptor antagonist on the induction by lipopolysaccharide of fever and brain interleukin-1beta response in rats.

Authors:  Hideki Shimizu; Michio Miyoshi; Kenji Matsumoto; Osamu Goto; Toshiaki Imoto; Tatsuo Watanabe
Journal:  J Pharmacol Exp Ther       Date:  2003-11-14       Impact factor: 4.030

10.  Angiotensin II AT1 receptor blockade decreases lipopolysaccharide-induced inflammation in the rat adrenal gland.

Authors:  Enrique Sanchez-Lemus; Yuki Murakami; Ignacio M Larrayoz-Roldan; Armen J Moughamian; Jaroslav Pavel; Tsuyoshi Nishioku; Juan M Saavedra
Journal:  Endocrinology       Date:  2008-06-12       Impact factor: 4.736

View more
  20 in total

1.  Oxytocin Receptors Are Expressed by Glutamatergic Prefrontal Cortical Neurons That Selectively Modulate Social Recognition.

Authors:  Yalun Tan; Sarthak M Singhal; Scott W Harden; Karlena M Cahill; Dan-Tam M Nguyen; Luis M Colon-Perez; Todd J Sahagian; Jeffrey S Thinschmidt; Annette D de Kloet; Marcelo Febo; Charles J Frazier; Eric G Krause
Journal:  J Neurosci       Date:  2019-02-25       Impact factor: 6.167

Review 2.  Centrally Mediated Cardiovascular Actions of the Angiotensin II Type 2 Receptor.

Authors:  U Muscha Steckelings; Annette de Kloet; Colin Sumners
Journal:  Trends Endocrinol Metab       Date:  2017-07-18       Impact factor: 12.015

Review 3.  Hypothalamic Signaling in Body Fluid Homeostasis and Hypertension.

Authors:  Brian J Kinsman; Haley N Nation; Sean D Stocker
Journal:  Curr Hypertens Rep       Date:  2017-06       Impact factor: 5.369

4.  (Pro)renin receptor knockdown in the paraventricular nucleus of the hypothalamus attenuates hypertension development and AT1 receptor-mediated calcium events.

Authors:  Lucas A C Souza; Caleb J Worker; Wencheng Li; Fatima Trebak; Trevor Watkins; Ariana Julia B Gayban; Evan Yamasaki; Silvana G Cooper; Bernard T Drumm; Yumei Feng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-03-29       Impact factor: 4.733

5.  Angiotensin receptor expression revealed by reporter mice and beneficial effects of AT2R agonist in retinal cells.

Authors:  Amrisha Verma; Ping Zhu; Annette de Kloet; Eric Krause; Colin Sumners; Qiuhong Li
Journal:  Exp Eye Res       Date:  2019-08-23       Impact factor: 3.467

6.  A-type K+ channels contribute to the prorenin increase of firing activity in hypothalamic vasopressin neurosecretory neurons.

Authors:  Soledad Pitra; Javier E Stern
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-16       Impact factor: 4.733

Review 7.  Protective Angiotensin Type 2 Receptors in the Brain and Hypertension.

Authors:  Annette D de Kloet; Ulrike M Steckelings; Colin Sumners
Journal:  Curr Hypertens Rep       Date:  2017-06       Impact factor: 5.369

Review 8.  The intricacies of the renin-angiotensin-system in metabolic regulation.

Authors:  Erin B Bruce; Annette D de Kloet
Journal:  Physiol Behav       Date:  2016-11-22

9.  Brain angiotensin type-1 and type-2 receptors: cellular locations under normal and hypertensive conditions.

Authors:  Colin Sumners; Amy Alleyne; Vermalí Rodríguez; David J Pioquinto; Jacob A Ludin; Shormista Kar; Zachary Winder; Yuma Ortiz; Meng Liu; Eric G Krause; Annette D de Kloet
Journal:  Hypertens Res       Date:  2019-12-18       Impact factor: 3.872

10.  Limbic Neuropeptidergic Modulators of Emotion and Their Therapeutic Potential for Anxiety and Post-Traumatic Stress Disorder.

Authors:  Paul J Marvar; Raül Andero; Rene Hurlemann; Tiffany R Lago; Moriel Zelikowsky; Joanna Dabrowska
Journal:  J Neurosci       Date:  2021-01-20       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.